Skip to content

Study · Ex vivo tissue · hybrid striped bass (morone saxatilis x m. chrysops) · 2002

3 results

Characterization of pituitary IGF-I receptors: modulation of prolactin and growth hormone.

Fruchtman S, McVey DC, Borski RJ

American journal of physiology. Regulatory, integrative and comparative physiology1 Aug 2002Cited by 21 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In hybrid striped bass pituitary tissue, Des(1‑3)IGF-I inhibited saturable labeled IGF-I binding similarly to IGF-I.

    In plain wordsIn lab tests, Des(1‑3)IGF-I and IGF-I similarly inhibited labeled IGF-I binding in hybrid striped bass pituitary tissue.

    Outcome
    No significant changeInhibition of saturable IGF-I binding
    Study

    hybrid striped bass (Morone saxatilis x M. chrysops)n: not reported in source

    pituitary gland
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Des(1-3)IGF-I, a truncated analog of IGF-I that binds with high affinity to IGF-I receptors but weakly to IGF-I binding proteins (IGFBPs), showed a similar inhibition of saturable (125)I-IGF-I binding, but it was more potent than IGF-I in stimulating PRL and inhibiting GH release.
    1 context sentence
    Summary · context
    We show that IGF-I binds with high affinity and specificity to the pituitary gland of hybrid striped bass (Morone saxatilis x M. chrysops).
  2. 02LabEx vivo tissueEfficacy outcome

    In hybrid striped bass pituitary tissue, Des(1‑3)IGF-I stimulated prolactin release more potently than IGF-I.

    In plain wordsIn lab tests, Des(1‑3)IGF-I stimulated prolactin release more potently than IGF-I in hybrid striped bass pituitary tissue.

    Outcome
    IncreaseProlactin release
    Study

    hybrid striped bass (Morone saxatilis x M. chrysops)n: not reported in source

    pituitary gland
    Comparator
    IGF-I
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Des(1-3)IGF-I, a truncated analog of IGF-I that binds with high affinity to IGF-I receptors but weakly to IGF-I binding proteins (IGFBPs), showed a similar inhibition of saturable (125)I-IGF-I binding, but it was more potent than IGF-I in stimulating PRL and inhibiting GH release.
    1 context sentence
    Summary · context
    We show that IGF-I binds with high affinity and specificity to the pituitary gland of hybrid striped bass (Morone saxatilis x M. chrysops).
  3. 03LabEx vivo tissueEfficacy outcome

    In hybrid striped bass pituitary tissue, Des(1‑3)IGF-I inhibited growth hormone release more potently than IGF-I.

    In plain wordsIn lab tests, Des(1‑3)IGF-I inhibited growth hormone release more potently than IGF-I in hybrid striped bass pituitary tissue.

    Outcome
    DecreaseGrowth hormone release
    Study

    hybrid striped bass (Morone saxatilis x M. chrysops)n: not reported in source

    pituitary gland
    Comparator
    IGF-I
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Des(1-3)IGF-I, a truncated analog of IGF-I that binds with high affinity to IGF-I receptors but weakly to IGF-I binding proteins (IGFBPs), showed a similar inhibition of saturable (125)I-IGF-I binding, but it was more potent than IGF-I in stimulating PRL and inhibiting GH release.
    1 context sentence
    Summary · context
    We show that IGF-I binds with high affinity and specificity to the pituitary gland of hybrid striped bass (Morone saxatilis x M. chrysops).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.